Document:

EX-10.2

 Exhibit 10.2 

COLLABORATION AGREEMENT 
 by and
between 
 UROVANT SCIENCES GMBH 

and 
 KYORIN PHARMACEUTICAL CO.,
LTD. 
  
  

Dated as of August 24, 2017 
  

 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 COLLABORATION AGREEMENT 

This Collaboration Agreement (this “Agreement”) dated August 24, 2017 (“Effective Date”), is by and
between Urovant Sciences GmbH, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”), and Kyorin Pharmaceutical Co., Ltd., having a place of business at 6, Kanda Surugadai
4-chome, Chiyoda-ku, Tokyo 101-8311, Japan (“Kyorin”). 

RECITALS 
 WHEREAS,
Urovant is a pharmaceutical company engaged in the research, development, and commercialization of products useful in the amelioration, treatment, or prevention of human diseases and conditions in the field of Urology; 

WHEREAS, Kyorin is a pharmaceutical company engaged in the research, development, and commercialization of products useful in the
amelioration, treatment, or prevention of human diseases and conditions in a variety of fields, including Urology; 
 WHEREAS,
Urovant and Kyorin have obtained from Merck Sharp & Dohme Corp. certain licenses to products containing an active pharmaceutical ingredient called Vibegron (also known as MK-4618) in their respective
territories; 
 WHEREAS, Urovant and Kyorin made the Letter Agreement, in which the Parties confirmed their understanding of the
exchange of certain confidential technical and business information and other collaboration relationship items relating to Vibegron; 

WHEREAS, Urovant and Kyorin desire to enter into an agreement to specify the provisions of an additional information exchange,
specifically SAS datasets and portions of trial master files (“TMFs”), and other collaboration relationship items, and to set forth certain additional provisions related hereto. 

NOW, THEREFORE, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

  

	1.1	“Affiliate” of a Party to this Agreement means and includes any Person: (a) fifty percent (50%) or more of the voting stock or other equity interest of which is owned, directly or
indirectly, by that Party; (b) which owns, directly or indirectly, fifty percent (50%) or more of the voting stock or other equity interest of that Party; (c) fifty percent (50%) or more of the voting stock or other equity interest of
which is owned, directly or indirectly, by a Person that owns, directly or indirectly, fifty percent (50%) or more of the voting stock or other equity interest of that Party; (d) for which that Party has the right to elect a majority of the
members of the board of directors, or to appoint the chief executive officer, general manager or other senior management officials; or (e) that possesses, directly or indirectly, the power to direct, or cause the direction of, the management
and policies of that Party. 

  

	1.2	“Agreement” has the meaning set forth in the Preamble. 

  
 -2- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	1.3	“Applicable Laws” means all applicable laws, regulations, rules, decrees, judicial and administrative orders, and governmental actions, policies and requirements having the force of law in the
applicable country or jurisdiction. 

  

	1.4	“Business Day” means a day other than a Saturday, Sunday, a bank or other public holiday in the United States or Japan, or a day designated by a Party as its
non-business day. 

  

	1.5	“CCDS” means company core data sheet. 

  

	1.6	“Change of Control” means the sale of all or substantially all the assets or the equity of a Party to a Third Party; or any merger, consolidation or acquisition of a Party with, by or into any
Third Party. 

  

	1.7	“Clinical Trial” means any human clinical trial of Vibegron, including any “Phase IV” post-approval clinical trial. 

 

	1.8	“CMC” means chemistry, manufacturing, and controls. 

  

	1.9	“Commercialize” or “Commercialization” means all activities carried out in the commercialization of Vibegron, including distributing (including, without limitation, importing,
exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering Vibegron to customers), advertising, promoting, marketing, using and selling Vibegron, and booking sales, as applicable. 

 

	1.10	“Confidential Information” means (a) information not in the public domain that is disclosed by one Party or its Affiliates to the other Party or its Affiliates in connection with this
Agreement and/or the Letter Agreement, including all Kyorin Information, Urovant Information, and all other data and information relating to Vibegron or the business, marketing, promotion, affairs, research and development activities, results of
clinical and non-clinical studies, national and multinational regulatory proceedings and affairs, finances, manufacturing, plans, contractual relationships and operations of either Party or their Affiliates
which is disclosed or provided by or on behalf of one Party to the other Party in connection with this Agreement and (b) the terms and conditions contained in this Agreement that are not in the public domain. 

 

	1.11	“Control” or “Controlled” means, with respect to any information, documentation or Regulatory Materials, the legal authority or right (whether by ownership, license (other than a
license granted pursuant to this Agreement) or otherwise) of a Party or its relevant Affiliate, to grant access or rights to such information, documentation or Regulatory Materials to the other Party as set forth herein without (a) breaching
the terms of any agreement with a Third Party, (b) misappropriating the proprietary or trade secret information of a Third Party, (c) necessitating the consent of a Third Party or (d) requiring any royalty or other payment to any
Third Party. 

  

	1.12	 “Develop” or “Development” means the conduct of any and all non-clinical and clinical research and development, including, among other things: drug discovery, toxicology studies, DMPK studies and other non-clinical efforts, statistical
analysis, the design and 

  
 -3- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
conduct of any Clinical Trials, formulation, or regulatory activities relating to Vibegron, that are reasonably required or useful to obtain or maintain any regulatory approvals of Vibegron.

  

	1.13	“Disclosing Party” has the meaning set forth in Section 4.1 (Nondisclosure and Non-Use). 

 

	1.14	“Dispute” has the meaning set forth in Section 5.1 (Dispute Resolution). 

  

	1.15	“DMPK” means drug metabolism and pharmacokinetics. 

  

	1.16	“Effective Date” has the meaning set forth in the Preamble. 

  

	1.17	“FDA” means the U.S. Food and Drug Administration. 

  

	1.18	“Government Authority” means any national, regional, municipal, country, or other governmental, quasi-governmental, administrative or regulatory agency, body or other similar entity in a given
jurisdiction, including the FDA, EMA, and PMDA. 

  

	1.19	“ICH” means International Conference on Harmonization. 

  

	1.20	“IND” means a clinical trial authorization application filed for Vibegron with the applicable Government Authority in any country prior to beginning a Clinical Trial in that country (including an
investigational new drug application filed with the FDA) or other documentation issued by a Government Authority that permits the conduct of clinical testing of Vibegron in humans in a regulatory jurisdiction. 

 

	1.21	“Indication” means the use of Vibegron for the treatment, prevention, cure or control of a specific human disease, disorder, illness or condition. 

 

	1.22	“Kyorin” has the meaning set forth in the Preamble. 

  

	1.23	“Kyorin Indemnitee” has the meaning set forth in Section 6.1 (Indemnification by Urovant). 

  

	1.24	“Kyorin Information” has the meaning set forth in Section 2.1 (Share of Information). 

  

	1.25	“Kyorin Territory” means Japan, Korea, Taiwan, Hong Kong, Indonesia, Cambodia, Singapore, Thailand, the Philippines, Brunei, Vietnam, Malaysia, Myanmar, and Laos. 

 

	1.26	“Letter Agreement” means that letter agreement executed by the duly authorized representatives of the Parties on April 11, 2017. 

 

	1.27	“Losses” has the meaning set forth in Section 6.1 (Indemnification by Urovant). 

  

	1.28	“MAA” means an application to the appropriate Government Authority for approval to commercially sell Vibegron (but excluding pricing approval) in a particular jurisdiction (including, without
limitation, a new drug application in the United States) and all amendments and supplements thereto. 

  
 -4- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	1.29	“Manufacture” or “Manufacturing” means all activities by or on behalf of a Party related to the manufacturing of Vibegron, or any ingredient thereof, including but not limited to
test method development and stability testing, formulation, process development, manufacturing for use in non-clinical or clinical studies, manufacturing scale-up,
manufacturing Vibegron for Development or Commercialization, labeling, filling, processing, quality assurance/quality control development, quality control testing (including in-process release and stability
testing), packaging, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, and regulatory activities related to all of the foregoing. 

 

	1.30	“Party” means each of Urovant or Kyorin, as applicable and “Parties” means both of Urovant and Kyorin; [***]. 

 

	1.31	“Person” means any individual, corporation, partnership, limited liability company, trust, governmental entity, or other legal entity of any nature whatsoever. 

 

	1.32	“Pharmacovigilance Agreement” has the meaning set forth in Section 2.6 (Pharmacovigilance Agreement). 

  

	1.33	“Pivotal Study” means a study listed in the “clinical studies” section (which, as of the Effective Date, is section 14) of an FDA approved package insert. 

 

	1.34	“PMDA” means the Pharmaceuticals and Medical Devices Agency in Japan. 

  

	1.35	“Receiving Party” has the meaning set forth in Section 4.1 (Nondisclosure and Non-Use). 

 

	1.36	“Regulatory Materials” means all regulatory applications, registrations, licenses, authorizations and approvals, all correspondence submitted to or received from a Government Authority (including
minutes and official contact reports relating to any communications with any Government Authority), and all reports and documentation in connection with all clinical and non-clinical studies and tests
(including study reports and study protocols, and copies of all interim study analysis, but excluding Module 3 of the Common Technical Document, Manufacturing data, and drug master files, unless otherwise agreed by the Parties) submitted to any
Government Authority, and all data contained in any of the foregoing, including all INDs, clinical and non-clinical data, adverse event files and complaint files, in each case related to Vibegron.

  

	1.37	[***]. 

  

	1.38	“Term” has the meaning set forth in Section 7.1 (Term). 

  

	1.39	“Terminated Party” has the meaning set forth in Section 7.5 (Effect of Expiration or Termination). 

  

	1.40	“Terminating Party” has the meaning set forth in Section 7.5 (Effect of Expiration or Termination). 

  
 -5- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	1.41	“Third Party” means a Person other than Kyorin or Urovant, or any of their Affiliates. 

  

	1.42	“Urology” means the treatment of diseases primarily affecting the male and female urinary tract and/or urinary bladder, excluding oncology, osteoporosis, and kidney indications.

  

	1.43	“Urology Asset License” has the meaning set forth in Section 2.8 (Kyorin Right of First Review and Negotiation). 

 

	1.44	“Urology Rights” has the meaning set forth in Section 2.8 (Kyorin Right of First Review and Negotiation). 

 

	1.45	“Urovant” has the meaning set forth in the Preamble. 

  

	1.46	“Urovant Indemnitee” has the meaning set forth in Section 6.2 (Indemnification by Kyorin). 

  

	1.47	“Urovant Information” has the meaning set forth in Section 2.1 (Share of Information). 

  

	1.48	“Urovant Territory” means the entire world excluding the Kyorin Territory. 

  

	1.49	“Vibegron” means any and all pharmaceutical products with any kinds of strength, dosage form, and formulations containing [***] as an active pharmaceutical ingredient, either alone or in
combination with one or more other active pharmaceutical ingredient(s). 

 ARTICLE 2 

COLLABORATION ON INFORMATION SHARE 
  

	2.1	Share of Information. In accordance with the provisions of this Section 2.1 (Share of Information), each Party shall provide to the other Party all information useful or
reasonably necessary for the other Party to Develop and Commercialize Vibegron in the other Party’s Territory to the extent available to such providing Party. For clarity, each Party shall not be required to provide to the other Party any
information relating to CMC or Manufacturing except as otherwise agreed by the Parties. For further clarity, each Party shall not be required to translate any information or provide any original hardcopy or any original file of any information for
the purposes of this Section 2.1 (Share of Information). Notwithstanding the foregoing, the Party providing its information hereunder may request the other Party to arrange, at its cost, for a Third Party agent or contractor to be sent out to
an office of such providing Party or any other place designated by the providing Party to take copies of, or computerize such information, or compensate the providing Party for the costs incurred by the providing Party to take copies of, or
computerize such information, which include the cost of a full-time employee of the providing Party. 

  

	 	(a)	 Urovant Information. Urovant shall, within ten (10) Business Days after the date of the request from
Kyorin unless otherwise agreed by the Parties, provide to Kyorin the information listed in Appendix 1 attached hereto. Urovant shall, within ten (10) Business Days after the date of receipt of the finalized minutes of the End of Phase 2 meeting
for Vibegron with the FDA, provide a copy of such minutes to Kyorin. 

  
 -6- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
Such information and minutes provided by or on behalf of Urovant to Kyorin in connection with this Agreement (the “Urovant Information”) shall, as between the Parties, remain the
sole property of Urovant. Unless otherwise provided for in this Agreement, Kyorin (i) may use such Urovant Information only for the purpose of the fulfillment of obligations or the exercise of rights under this Agreement, (ii) shall not
use any Urovant Information for any purpose other than as set forth in subsection (i) above, or for the benefit of any Third Party (other than a Kyorin sublicensee and consistent with subsection (i) above), without obtaining Urovant’s
prior written consent, and (iii) shall not provide or otherwise make accessible to any Third Party any Urovant Information for any purpose other than as set forth in subsection (i) above (other than a Kyorin sublicensee(s) and consistent
with subsection (i) above), without obtaining Urovant’s prior written consent; in each case, in accordance with Article 4 (Confidentiality). 

  

	 	(b)	Kyorin Information. Both Parties acknowledge that under the Letter Agreement Kyorin agreed to provide and has provided to Urovant, and Urovant agreed to receive and has received from Kyorin, the information
listed in Appendix 2 attached hereto. Kyorin shall, promptly after the Effective Date and no later than ten (10) Business Days after the Effective Date, provide to Urovant the information listed in Appendix 3 attached hereto,
including patient-level data as agreed under the Letter Agreement, in the form of the CSR. Kyorin shall, no later than ten (10) Business Days after the date of PMDA’s acceptance of the MAA submitted by Kyorin to PMDA unless otherwise
agreed by the Parties, provide to Urovant the information listed in Appendix 4 attached hereto. Such information provided by or on behalf of Kyorin to Urovant in connection with this Agreement (the “Kyorin Information”) shall, as
between the Parties, remain the sole property of Kyorin. Unless otherwise provided for in this Agreement, Urovant (i) may use such Kyorin Information only for the purpose of the fulfillment of obligations or the exercise of rights under this
Agreement, (ii) shall not use any Kyorin Information for any purpose other than as set forth in subsection (i) above, or for the benefit of any Third Party (other than a Urovant sublicensee and consistent with subsection (i) above),
without obtaining Kyorin’s prior written consent, and (iii) shall not provide or otherwise make accessible to any Third Party any Kyorin Information for any purpose other than as set forth in subsection (i) above (other than a Urovant
sublicensee(s) and consistent with subsection (i) above), without obtaining Kyorin’s prior written consent; in each case, in accordance with Article 4 (Confidentiality). 

 

	2.2	 Urovant Right of Reference. Kyorin hereby grants to Urovant (and its Affiliates or its
sublicensees) access to, and a right of reference with respect to, all Regulatory Materials Controlled by Kyorin and corresponding documentation, solely for the purposes of (a) Commercializing Vibegron in the Urovant Territory, and
(b) Developing Vibegron in the Urovant Territory (including the use for any meeting with or any submission to the relevant Government Authority, itself or through its sublicensees, for the purpose of obtaining any regulatory approvals of
Vibegron for any Indication), in each case, in accordance with all Applicable Laws. If Urovant requests Kyorin’s assistance to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be

  
 -7- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
necessary or appropriate in order to effect such right of reference, Urovant shall inform Kyorin of such request, and the Parties shall discuss and agree in writing on the terms and conditions
for such assistance; provided, that Kyorin shall, without making any written agreement thereunder, use commercially reasonable efforts to timely answer any questions from Urovant in order to effect the right of reference. 

 

	2.3	Kyorin Right of Reference. Urovant hereby grants to Kyorin (and its Affiliates or its sublicensees) access to, and a right of reference with respect to, Regulatory Materials Controlled by Urovant
and corresponding documentation, solely for the purposes of (a) Commercializing Vibegron in the Kyorin Territory, and (b) Developing Vibegron in the Kyorin Territory (including the use for any meeting with or any submission to the relevant
Government Authority, itself or through its sublicensees, for the purpose of obtaining any regulatory approvals of Vibegron for any Indication), in each case, in accordance with all Applicable Laws. If Kyorin requests Urovant’s assistance to
execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be necessary or appropriate in order to effect such right of reference, Kyorin shall inform Urovant of such request, and the Parties
shall discuss and agree on in writing the terms and conditions for such assistance; provided, that Urovant shall, without making any written agreement thereunder, use commercially reasonable efforts to timely answer any questions from Kyorin
in order to effect the right of reference. 

  

	2.4	Regulatory Cooperation. The Parties understand that the assistance under Section 2.2 (Urovant Right of Reference) and Section 2.3 (Kyorin Right of Reference) include the provisions of
relevant internal regulatory documents, such as notes and preparation materials, and any materials documenting any clarifications (whether orally or otherwise) regarding any Regulatory Materials or with respect to which the requesting Party has a
right of reference. For the avoidance of doubt, such Party shall not be required to translate any such Regulatory Materials or provide any original hardcopy or any original file of any Regulatory Material for the purposes of this Section 2.4
(Regulatory Cooperation). 

  

	2.5	Milestone Payments. Urovant shall pay the following milestone payments to Kyorin: 

  

	 	(a)	[***] within ten (10) Business Days of [***;] 

  

	 	(b)	[***] within ten (10) Business Days of [***]; 

  

	 	(c)	(1) If Kyorin receives [***] or (2) if Kyorin receives [***], within ten (10) Business Days of [***]; and 

  

	 	(d)	[***]. Such milestone payment shall be made within ten (10) Business Days of [***]. 

 For
clarity, the payments set forth in this Section 2.5 (Milestone Payments) shall be non-refundable. 
  

	2.6	 Pharmacovigilance Agreement. The Parties shall execute a pharmacovigilance agreement on
reasonable and customary terms that shall provide, among other things, guidelines and responsibilities for (a) the receipt, investigation, recording, review, 

  
 -8- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
communication, reporting, and exchange between the Parties of adverse event reports and other safety information relating to Vibegron such as CCDSs, Safety Signaling, core- RMP, Periodic /
Aggregate reports (DSUR, PBRER) without any consideration, (b) appropriate reconciliation procedures to ensure adequate and compliant exchange of safety data, (c) contact with Government Authorities with respect to the foregoing, and
(d) Urovant’s maintenance of a global safety database with respect to Vibegron at its cost, in each case ((a)–(d)), in accordance with Applicable Law (the “Pharmacovigilance Agreement”). The Pharmacovigilance
Agreement shall contain terms no less stringent than those required by ICH or other applicable guidelines to allow the Parties to meet the applicable regulatory and legal requirements regarding the management of safety data in their respective
Territories. 

  

	2.7	Disclosure of Collaboration. Without obtaining the prior written consent of the other Party, neither Party nor its Affiliates may disclose on its website or in its promotional materials that the
other Party is a partner of such Party, or utilize the other Party’s name and logo in conjunction with such disclosure. Further, any publication, news release or other public announcement made by a Party relating to this Agreement or to the
performance hereunder, shall first be reviewed and consented by the other Party; provided, that any disclosure required by Applicable Laws may be made without obtaining the prior written consent of the other Party. Each Party shall provide to
the other Party a draft of any public announcement regarding this Agreement or the subject matter thereof, regardless of whether consent is required, as soon as reasonably practicable under the circumstances prior to its scheduled release. Except
under extraordinary circumstances, each Party shall provide the other Party with an advance copy of any such announcement ten (10) Business Days prior to its scheduled release. Each Party shall have the right to expeditiously review and
recommend changes to any such announcement and, except as otherwise required by Applicable Laws, the Party whose announcement has been reviewed shall give good faith consideration to removing any information that the reviewing Party reasonably deems
to be inappropriate for disclosure. 

  

	2.8	 Kyorin Right of First Review and Negotiation. If, beginning on the Effective
Date and continuing for ten (10) years thereafter, Urovant obtains Japanese rights to any asset(s) for which the primary intended indication at the time of acquisition is Urology, other than Vibegron-related assets (“Urology
Rights”), Urovant shall promptly (but in no event later than thirty (30) days after the date of obtaining such Urology Rights), inform Kyorin that it has obtained such Urology Rights. If Kyorin is interested in evaluating such Urology
Rights, Kyorin shall promptly (but in no event later than ten (10) days after receiving notice from Urovant) inform Urovant of such interest. Urovant shall then promptly (but in no event later than thirty (30) days after receiving an
expression of interest from Kyorin), provide to Kyorin all data and information available to Urovant that is useful or reasonably necessary for evaluating its interest in such Urology Rights. If Kyorin desires to obtain a license to exercise the
Urology Rights (“Urology Asset License”), Kyorin shall, within sixty (60) days after the date of the last receipt of such data and information (which date shall not be extended by subsequent questions or requests from Kyorin),
submit to Urovant a non-binding term sheet proposing the basic terms for such Urology Asset License. Urovant shall consider such Kyorin term sheet and negotiate in good faith with Kyorin the

  
 -9- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
terms for the Urology Asset License for ninety (90) days after the date of the Kyorin term sheet. If the Parties fail to enter into a definitive agreement for the Urology Asset License by
the end of the ninety (90) day good faith negotiation period, Urovant shall have the right to negotiate and enter into such a definitive agreement with any Third Party without bearing further obligations to Kyorin. If Kyorin fails to submit to
Urovant the non-binding term sheet within such sixty (60) day period, then Urovant shall have no further obligation to Kyorin with respect to the Urology Rights. This Section 2.8 (Kyorin Right of
First Review and Negotiation) shall expire upon any Change of Control and shall not extend to any of Urovant’s licensees and sublicensees or its Affiliates’ licensees and sublicensees. 

 

	2.9	[***] 

 ARTICLE 3 

OTHER COLLABORATIONS 
  

	3.1	Other Collaborations. Urovant and Kyorin shall, from time to time during the Term, evaluate the possibility of further collaborations between the Parties on the Development and Commercialization of
Vibegron. 

 ARTICLE 4 

CONFIDENTIALITY 
  

	4.1	Nondisclosure and Non-Use. Each Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the
“Receiving Party”) receiving Confidential Information of the other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, (b) not disclose such Confidential Information to any Third Party (other than its sublicensee and consistent with
Section 2.1(a)(i) or Section 2.1(b)(i)) without obtaining the prior written consent of the Disclosing Party, except for disclosures expressly permitted in this Article 4 (Confidentiality), and (c) not use such Confidential Information
for any purpose, except to exercise its right and perform its obligations under this Agreement (it being understood that this Section 4.1 (Nondisclosure and Non-Use) shall not create or imply any rights
or licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the obligations of confidentiality and non-use with respect to any trade secret within such
Confidential Information shall survive for so long as such Confidential Information remains protected as a trade secret under Applicable Law. 

  

	4.2	Exceptions. The obligations in Section 4.1 (Nondisclosure and Non-Use) shall not apply with respect to any portion of the Confidential Information that
the Receiving Party can show by competent evidence: 

  

	 	(a)	is in the public domain at the time it is disclosed to the Receiving Party hereunder; 

  

	 	(b)	is known to the Receiving Party or any of its Affiliates at the time of its receipt without bearing any obligation to keep it confidential; 

  
 -10- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	(c)	is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party’s knowledge, is not bound
by a duty of confidentiality; 

  

	 	(d)	is now, or hereafter becomes, through no breach of this Agreement on the part of the Receiving Party or any of its Affiliates, publicly known or available, either before or after it is disclosed to the Receiving Party;

  

	 	(e)	is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the aid, use of, access to, or application of any of the Confidential Information belonging to the
Disclosing Party; or 

  

	 	(f)	is the subject of written permission to disclose provided by the Disclosing Party. 

  

	4.3	Authorized Disclosure. 

  

	 	(a)	Permitted Disclosure. Notwithstanding the provisions of Section 4.1 (Nondisclosure and Non-Use), the Receiving Party may disclose Confidential Information belonging to
the Disclosing Party in the following instances: (i) filing of Regulatory Materials in order to obtain or maintain MAAs and other regulatory approvals in its Territory; (ii) complying with Applicable Law or regulation or order of any court
or Government Authority, including responding to a subpoena in a Third Party litigation to the extent mandatory; and (iii) to its Affiliates and (in each case actual or potential) sublicensees, merger, acquisition or other business partners,
subcontractors, payors, employees, consultants, agents, and advisors on a “need-to-know” basis, each of whom prior to disclosure must be bound by obligations
of confidentiality and restrictions on use of such Confidential Information that are substantially similar to those set forth in this Article 4 (Confidentiality); or (iv) to (in each case actual or potential) investment bankers, investors,
lenders or financial partners, or their respective representatives on a “need-to-know” basis, each of whom prior to disclosure must be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are substantially similar to those set forth in this Article 4 (Confidentiality), except that, for all Confidential Information aside from SAS datasets and TMF, the
term of such confidentiality agreement may be shorter if in accordance with industry standards for investment bankers, investors, lenders or financial partners; provided, further, that the Receiving Party shall be liable for their
breaches thereto. 

  

	 	(b)	 Notice; Confidential Treatment. If and whenever any Confidential Information is disclosed in accordance
with this Section 4.3 (Authorized Disclosure), such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than
by breach of this Agreement). Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Section 4.3(a)(ii), then it shall, except where prohibited by Applicable
Law, (i) give reasonable prior written notice to the other 

  
 -11- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
Party of such disclosure and use not less than the same efforts to secure confidential treatment of or a protective (or similar) order for such Confidential Information as it would to protect its
own Confidential Information from disclosure and (ii) only disclose the minimum amount of Confidential Information reasonably required for the purpose of such disclosure, as advised by legal counsel. 

 

	4.4	Restricted Disclosure. 

  

	 	(a)	Notwithstanding any provisions of this Agreement, Urovant shall not disclose (i) [***] and (ii) [***]; provided, that Urovant shall be liable for any breach by such consultant or agent of obligations of
confidentiality or restrictions on use of the Kyorin Information set forth in subsection (i) and (ii) above. [***.] 

  

	 	(b)	Urovant represents and warrants to Kyorin as of the Effective Date that [***.] 

  

	 	(c)	If Urovant breaches any of its obligations, representations or warranties under subsections (a) and (b) above and Kyorin incurs damages due to such breach, then Urovant shall, at Kyorin’s option, either
(i) compensate Kyorin for its damages [***] or (ii) pay [***] as liquidated damages. [***]. 

 ARTICLE 5 

DISPUTE RESOLUTION 
  

	5.1	Dispute Resolution. In the event of any disputes, claims or controversies arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof
between the Parties (each, a “Dispute”), the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves on an informal basis, facilitated by each Party’s Contact Person,
for a period of ten (10) Business Days after the date of the receipt of a written notice of such Dispute by a Party. If such Dispute is not resolved within such ten (10) Business Day period, either Party may, by giving written notice to
the other Party, refer the Dispute to the senior executive officer (or his or her delegate) of the other Party for attempted resolution by good faith negotiation within thirty (30) days after the date of the expiration of such ten
(10) Business Day period. Each Party may, in its sole discretion, seek resolution of any and all Disputes that are not resolved under this Section 5.1 (Dispute Resolution) in accordance with Section 5.2 (Arbitration).

  

	5.2	Arbitration. Any unresolved Dispute which was subject to Section 5.1 (Dispute Resolution) shall be settled by binding arbitration in accordance with the International Chamber of Commerce
(ICC) rules of arbitration. Any demand by a Party for arbitration must be made in writing to the other Party. The number of arbitrators shall be three (3), of whom each Party shall appoint one (1). The two arbitrators so appointed shall
select the third and final arbitrator. The place of arbitration shall be Tokyo, Japan if arbitration is requested by Urovant and Basel, Switzerland if arbitration is requested by Kyorin. The language used in the arbitration proceedings shall be
English. The proceedings, including any outcome, shall be confidential. The arbitrators shall render a written opinion setting forth the findings of fact and conclusions of law. The decision of the arbitrators shall be final and binding upon both
Parties absent manifest error. All awards may if necessary be enforced by any court having jurisdiction in the same manner as a judgment in such court. 

  
 -12- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	5.3	Injunctive Relief. Notwithstanding the foregoing, in the event of an actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific
performance or other injunctive relief) in any court of competent jurisdiction, without first submitting to the dispute resolution procedures set forth in Section 5.1 (Dispute Resolution) or Section 5.2 (Arbitration). 

 

	5.4	Confidentiality. Activities conducted under this Article 5 (Dispute Resolution) shall be deemed Confidential Information of each of the Parties, and shall be subject to the terms
of Article 4 (Confidentiality). 

 ARTICLE 6 

INDEMNIFICATION 
  

	6.1	Indemnification by Urovant. Urovant shall save, defend and hold Kyorin and its Affiliates and its and their respective directors, officers, employees and agents (each, a “Kyorin
Indemnitee”) harmless from and against any and all liabilities, expenses and losses, including reasonable legal expenses and attorneys’ fees (collectively, “Losses”), to which any Kyorin Indemnitee may become subject
as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (a) the negligence or willful misconduct of any Urovant Indemnitee in performing under this
Agreement, (b) the breach by Urovant of any warranty, representation, covenant or agreement made by Urovant in this Agreement or (c) any activities by Urovant or its Affiliates or their respective sublicensees or subcontractors with
respect to Vibegron, except, in each case, to the extent such Losses result from clause (a), (b) or (c) of Section 6.2 (Indemnification by Kyorin). 

  

	6.2	Indemnification by Kyorin. Kyorin shall save, defend and hold Urovant, its Affiliates, its licensees and their respective directors, officers, employees and agents (each, a “Urovant
Indemnitee”) harmless from and against any and all Losses to which any Urovant Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or
indirectly out of: (a) the negligence or willful misconduct of any Kyorin Indemnitee in performing under this Agreement, (b) the breach by Kyorin of any warranty, representation, covenant or agreement made by Kyorin in this Agreement or
(c) any activities by Kyorin or its Affiliates or their respective sublicensees or subcontractors with respect to Vibegron, except, in each case, to the extent such Losses result from clause (a), (b) or (c) of Section 6.1
(Indemnification by Urovant). 

  

	6.3	 Control of Defense. The Party entitled to indemnification under this Article 6
(Indemnification) shall give a written notice to the indemnifying Party of any Losses that may be subject to indemnification promptly after learning of such Losses (provided, however, that any failure or delay to notify shall not excuse any
obligation of the indemnifying Party except to the extent such Party is actually prejudiced thereby), and the indemnifying Party shall assume (and have control over) the defense of such Losses with

  
 -13- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
counsel reasonably satisfactory to the indemnified Party and the indemnified Party shall reasonably cooperate with such defense (at the indemnifying Party’s reasonable expense). If such
defense is assumed by the indemnifying Party with counsel so selected, the indemnifying Party shall not settle any claim with respect to such Losses without obtaining the indemnified Party’s prior written consent (but such consent shall not be
unreasonably withheld or delayed), and shall not be obligated to pay the fees and expenses of any separate counsel retained by the indemnified Party with respect to such Losses. For clarity, the indemnified Party may freely withhold its consent to a
settlement of a claim with respect to Losses if (a) such settlement does not include a complete release from liability of the indemnified Party or if such settlement would involve undertaking an obligation (including the payment of money by an
indemnified Party), (b) would bind or impair the indemnified Party or (c) includes any admission of wrongdoing or that any intellectual property or proprietary right of the indemnified Party or this Agreement is invalid, narrowed in scope or
unenforceable. The indemnified Party shall not settle or compromise any claim for which it is entitled to indemnification without obtaining the prior written consent of the indemnifying Party, unless the indemnifying Party is in breach of its
obligation to defend hereunder. 

 ARTICLE 7 

TERM AND TERMINATION 
  

	7.1	Term. This Agreement shall become effective on the Effective Date and shall continue for so long as both Parties (or their sublicensees or Affiliate(s)) are Developing or Commercializing Vibegron,
unless otherwise extended or terminated earlier by agreement of the Parties or as set forth in Section 7.2 (Termination for Material Breach), Section 7.3 (Termination for Change of Control), or Section 7.4 (Termination by Urovant
Before Receipt of SAS Dataset). 

  

	7.2	Termination for Material Breach. Each Party shall have the right to terminate this Agreement by giving sixty (60) days’ prior written notice to the other Party for the material breach of
this Agreement, if such other Party has not cured such material breach within the sixty (60)-day period after the date of the receipt of such written notice. For clarity, any breach by Urovant of any of its
obligations, representation or warranties under Section 4.4(a) and (b) shall be deemed a material breach of this Agreement, and in such case, this Section 7.2 (Termination for Material Breach) shall apply in addition to
Section 4.4(c). Notwithstanding the foregoing, if the allegedly breaching Party notifies the other Party within such sixty (60)-day period that it disagrees in good faith with such asserted basis for
termination, this Agreement shall not terminate unless and until it has been finally determined in accordance with Article 5 (Dispute Resolution) that the allegedly breaching Party was in material breach with respect to such matter. During the
pendency of any such dispute, each Party shall continue to perform its obligations hereunder. 

  

	7.3	Termination for Change of Control. Each Party shall have the right to terminate this Agreement by giving sixty (60) days’ prior written notice to the other Party if a Change of Control
occurs to the other Party. 

  
 -14- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	7.4	Termination by Urovant Before Receipt of SAS Dataset. Urovant shall have the right to terminate this Agreement prior to receipt of Kyorin’s SAS dataset, upon written notice to Kyorin.

  

	7.5	Effect of Expiration or Termination. 

  

	 	(a)	Termination for Material Breach. Upon the termination of this Agreement by either Party (the “Terminating Party”) pursuant to Section 7.2 (Termination for Material Breach):

  

	 	(i)	The rights granted by the Terminating Party to the other Party (the “Terminated Party”) under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference),
as applicable, shall terminate. 

  

	 	(ii)	The rights granted by the Terminated Party to the Terminating Party under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference) shall continue. 

 

	 	(iii)	The Terminated Party shall promptly, in accordance with the request of the Terminating Party, delete or destroy (such destruction to be certified in writing by an officer of such Party) all Confidential Information and
Regulatory Materials of the Terminating Party; provided, that the Terminated Party may keep one copy of such Confidential Information for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, the Terminated Party shall not be required to destroy any computer files created during automatic system back
up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Terminating Party’s Confidential Information under this Agreement. 

 

	 	(iv)	If Kyorin is the Terminating Party, then Kyorin’s rights and Urovant’s obligations under Section 2.8 (Kyorin Right of First Review and Negotiation) and Section 2.9 (Urovant Change of Control) shall
continue for so long as Kyorin’s rights under Section 7.5(a)(ii) continue. 

  

	 	(v)	If Kyorin is the Terminated Party, then Kyorin’s rights and Urovant’s obligations under Section 2.8 (Kyorin Right of First Review and Negotiation) and Section 2.9 (Urovant Change of Control) shall
terminate. 

  

	 	(b)	Termination for Change of Control. Upon the termination of this Agreement by either Party pursuant to Section 7.3 (Termination for Change of Control): 

 

	 	(i)	The rights of both Parties granted under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference) shall terminate. 

  
 -15- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	(ii)	Each Receiving Party shall promptly, in accordance with the request of the Disclosing Party, delete or destroy (such destruction to be certified in writing by an officer of such Party) all Confidential Information and
Regulatory Materials of such Disclosing Party; provided, that such Receiving Party may keep one copy of such Confidential Information for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, such Receiving Party shall not be required to destroy any computer files created during automatic system back
up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party’s Confidential Information under this Agreement. 

 

	 	(c)	Termination by Urovant Before Receipt of SAS Dataset. Upon the termination of this Agreement by Urovant pursuant to Section 7.4 (Termination by Urovant Before Receipt of SAS Dataset): 

 

	 	(i)	The rights of both Parties granted under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference) shall terminate. 

 

	 	(ii)	Kyorin’s rights and Urovant’s obligations under Section 2.8 (Kyorin Right of First Review and Negotiation), Section 2.9 (Urovant Change of Control) and, upon Urovant’s deletion or destruction of
CSRs (such deletion or destruction to be certified in writing by an officer of Urovant) if Urovant does not keep one copy of CSRs despite Section 7.5(c)(iii), Section 4.4 (Restricted Disclosure) shall terminate. 

 

	 	(iii)	Each Receiving Party shall promptly, in accordance with the request of the Disclosing Party, delete or destroy (such deletion or destruction to be certified in writing by an officer of such Party) all Confidential
Information and Regulatory Materials of such Disclosing Party; provided, that such Receiving Party may keep one copy of such Confidential Information for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, such Receiving Party shall not be required to destroy any computer files created during automatic system back up
that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party’s Confidential Information under this Agreement. 

 

	7.6	 Survival. The following provisions of this Agreement shall survive termination:
Article 4 (Confidentiality), Article 5 (Dispute Resolution), Article 6 (Indemnification), Section 7.5 (Effect of Expiration or Termination), Section 7.6 (Survival), and Article 8 (Miscellaneous). Termination or
expiration of this Agreement are neither Party’s exclusive remedy and shall neither relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either
Party from pursuing all rights and remedies it may have hereunder or at law or in equity 

  
 -16- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
with respect to any breach of this Agreement, nor prejudice either Party’s right to obtain performance of any obligation. In the event that, following the effective date of termination under
Section 7.2 (Termination for Material Breach), the Terminating Party fails to comply with the surviving provisions above, the Terminated Party shall have the right to terminate the Terminating Party’s rights under Section 7.5(a)(ii)
by following the procedures set forth in Section 7.2 (Termination for Material Breach). Following such termination, Section 7.5(a)(i) and (iii) shall apply mutatis mutandis (with the formerly Terminating Party deemed to be the
Terminated Party, but for clarity, the formerly Terminated Party shall not be deemed to be the Terminating Party). 

ARTICLE 8 
 MISCELLANEOUS

  

	8.1	No Implied Licenses. No license or other right is or shall be created or granted hereunder by implication, estoppel, or otherwise. All rights are or shall be granted only as expressly provided in
this Agreement. 

  

	8.2	Mutual Representations, Warranties and Covenants. Each of the Parties hereby represents and warrants to the other Party as of the Effective Date and covenants that: 

 

	 	(a)	Organization. It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise,
to execute, deliver, and perform this Agreement. 

  

	 	(b)	Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. 

 

	 	(c)	Authorization. The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, instrument, or
understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any court or governmental body, or administrative or other
agency presently in effect applicable to such Party. 

  

	 	(d)	No Inconsistent Obligations. Neither Party is under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that
would impede the diligent and complete fulfillment of its obligations hereunder. 

  

	8.3	 No Other Representations or Warranties. NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS
ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. ANY INFORMATION PROVIDED PURSUANT TO THIS AGREEMENT IS MADE AVAILABLE ON AN “AS IS” BASIS
WITHOUT WARRANTY WITH RESPECT TO 

  
 -17- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
ACCURACY, COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. 

 

	8.4	Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without obtaining the prior written consent of the other Party, except that each Party may
assign its rights and obligations under this Agreement in whole or in part to one or more of its Affiliates without the consent of the other Party. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or
attempted assignment by either Party in violation of the terms of this Section 8.4 (Assignment) shall be null, void and of no legal effect. 

  

	8.5	Notices. Any notice to be given under this Agreement must be in writing and delivered either in person, or by (a) air mail (postage prepaid) requiring return receipt,
(b) international courier, or (c) e-mail to the Party to be notified at its address(es) given below, with delivery and read receipts requested, or at any address such Party may designate by a prior
written notice to the other Party in accordance with this Section 8.5 (Notices). Notice shall be deemed sufficiently given for all purposes upon: (i) if by air mail or courier, the date of actual receipt; or (ii) if by e-mail, the date of confirmation of receipt by the intended recipient. Notices shall be sent to: 

  

			
	For Urovant:	  	Urovant Sciences GmbH
		  	Viaduktstrasse 8
		  	4051 Basel
		  	Switzerland
		  	Attention: Sascha Bucher, VP, Head of Global Transactions
		  	Email: sascha.bucher@roivant.com
		
	Copy to:	  	Urovant Sciences, Inc.
		  	320 West 37th Street
		  	5th Floor
		  	New York, NY 10018
		  	Attention: Legal Department
		
	[***]	  	
		
	For Kyorin:	  	Kyorin Pharmaceutical Co., Ltd
		  	6, Kanda Surugadai 4-chome
		  	Chiyoda-ku, Tokyo 101-8311
		  	Japan
		  	Attention: Makoto Yanai, Senior Director, Business Development HQs
		  	Email: makoto.yanai@mb.kyorin-pharm.co.jp

  
 -18- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

			
	Copy to:	  	Kyorin Holdings, Inc.
		  	6, Kanda Surugadai 4-chome
		  	Chiyoda-ku, Tokyo 101-8311
		  	Japan
		  	Attention: Legal Department

  

	8.6	[***] 

  

	8.7	Force Majeure. Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (other than failure to make payment when due) by
reason of any event beyond such Party’s reasonable control including acts of God, fire, flood, explosion, earthquake, pandemic flu, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty or any
other event similar to those enumerated above; provided, that the affected Party shall use commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of
such occurrence. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party’s
failure or delay in performance due to force majeure must be given to the other Party as promptly as is reasonably practicable after its occurrence and such Party shall provide the other Party with monthly status updates for the duration of the
effect. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure. In no event shall any Party be required to prevent or settle any labor disturbance or dispute.

  

	8.8	No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any Person other than the Parties and their successors and permitted assigns, except
for the Persons expressly entitled to indemnification as provided in Article 6 (Indemnification) and only in accordance with the terms of Article 6 (Indemnification). 

 

	8.9	Entire Agreement. This Agreement and the Appendixes attached hereto and made a part hereof, contain every obligation and understanding between the Parties relating to the subject hereof and
merge all prior discussions, negotiations and agreements, including the Letter Agreement, between them, and none of the Parties shall be bound by any conditions, definitions, understandings, warranties or representations other than as expressly
provided or referred to herein. 

  

	8.10	Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the
provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable
provision such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

  

	8.11	 Waiver and Non-Exclusion of Remedies. Any term or
condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of

  
 -19- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

	 	
the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of
any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law
or otherwise available except as expressly set forth herein. 

  

	8.12	Relationship of the Parties. It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture
or agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other Party, without obtaining the prior written consent of the other Party to
do so. All Persons employed by a Party shall be employees of that Party and not of the other Party and all expenses and obligations incurred by reason of such employment shall be for the account and expense of such Party. 

 

	8.13	Construction; Rules of Construction. Interpretation of this Agreement shall be governed by the following rules of construction: (a) words in the singular shall be held to include the plural and
vice versa, and words of one gender shall be held to include the other gender as the context requires; (b) the word “including” and words of similar import when used in this Agreement shall mean “including without
limitation,” unless otherwise specified; (c) the word “or” shall not be exclusive (i.e., it shall be construed to mean “and/or”), except where the context clearly requires otherwise; (d) the titles and headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement; (e) each of the Parties has participated in the negotiation and drafting of this Agreement and if an
ambiguity or question of interpretation should arise, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or burdening either Party by virtue of the authorship of any of
the provisions in this Agreement or any interim drafts of this Agreement; (f) references to “days” shall mean calendar days, unless otherwise specified; and (g) a reference to any Person includes such Person’s successors and
permitted assigns. 

  

	8.14	Governing Law. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement or the Party’s
respective performance hereunder. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of Switzerland, without giving effect to any choice of law
principles that would require the application of the laws of a different country. 

  

	8.15	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This
Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 

[remainder of page intentionally left blank] 

  
 -20- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date, by
their duly authorized representatives. 
  

									
	Kyorin Pharmaceutical Co., Ltd.	 		 	Urovant Sciences GmbH
					
	By:	 	/s/ Minoru Hogawa	 		 	By:	 	/s/ Sascha Bucher
	Name:	 	Minoru Hogawa	 		 	Name: Sascha Bucher
	Title:	 	 Representative Director
 President &
Chief Executive Officer
	 		 	Title: VP, Head of Global Transactions
		 		 		 	[***]

  
 [Signature Page to
Collaboration Agreement] 
  

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 1 

Urovant to provide to Kyorin within [***] of Kyorin request 

[***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 2 

Previously provided to Urovant under the Letter Agreement 

[***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 3 
 Kyorin
to provide to Urovant within [***] of Effective Date 
 [***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 4 
 Kyorin
to provide to Urovant at the time specified below, unless otherwise agreed 
 [***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 5 
 Kyorin
Clinical Trials 
 [***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 Appendix 6 
 Kyorin
Non-Clinical Studies 
 [***] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406.EX-10.3

 Exhibit 10.3 

CHINA IP PURCHASE AGREEMENT 

This CHINA IP PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 12th day of June, 2017 (“Effective
Date”), by and between Urovant Sciences GmbH, a Switzerland limited liability company with an address of do Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland (“Seller”), and
Roivant Sciences GmbH, a Switzerland limited liability company with an address of c/o Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland (“Buyer”). Each of the Seller and the Buyer are
referred to in this Agreement as a “party” and together as the “parties”. 
 WHEREAS, the Buyer is an affiliate of the
Seller, and both the Buyer and the Seller are wholly-owned, indirect subsidiaries of Roivant Sciences Ltd.; 
 WHEREAS, the Seller is the
owner of all right, title, claim and interest in the Assigned Assets (defined below); 
 WHEREAS, as part of an internal reorganization,
Seller as the owner of Assigned Assets, desires to sell, assign, transfer, convey, grant and deliver to Buyer, all of Seller’s right, title, claim and interest in and to and Buyer desires and is willing to accept from Seller, the Assigned
Assets (defined below) “as-is”; and 
 NOW THEREFORE, in consideration of the mutual
covenants set forth herein the parties hereby represent, covenant and agree as follows: 
 1.    Sale of Assigned
Assets. Seller hereby sells, transfers, assigns, conveys, grants and delivers to Buyer, “as-is”, “where-is” and with all faults, effective as of
the Effective Date, to have and to hold forever, all of Seller’s right, title, claim and interest, that exists today or may exist in the future, in and to (i) any and all intellectual property rights, whether existing as of the Effective
Date or hereafter, solely in China, including, but not limited to, inventions (whether patentable or not), patents, patent applications, trademarks, trade names, service names, domain names, trade dress, copyrights, works of authorship, trade
secrets, know-how, data, intellectual property license agreements and any other proprietary information (including all rights to sue and recover and retain damages, costs and attorneys’ fees for past,
present and future infringement and any other rights relating to any of the foregoing), including those set forth in Schedule I, and further including any moral rights and/or goodwill and activities associated with any of the foregoing solely in
China; and (ii) all of the properties, assets, and agreements identified on Schedule I hereto solely as it relates to any rights or obligations in China (collectively (i) and (ii), the “Assigned Assets”). 

a.    The Assigned Assets shall be held and enjoyed by Buyer, its successors and assigns from and after
the date of such assignment as fully and entirely as the same would have been held and enjoyed by Seller had such assignment not been made. 

2.    As of the Effective Date, the Buyer hereby receives and accepts the assignment, transfer and conveyance of the
rights and properties hereby assigned, transferred and conveyed to it herein from Seller. 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 3.    Assignment of Agreements and Rights. Anything in this Agreement
to the contrary notwithstanding, this Agreement shall not constitute an agreement to assign, or an assignment of, any Assigned Asset or any claim or right or any benefit arising thereunder or resulting therefrom if an attempted assignment thereof
would constitute a breach or other contravention thereof or in any way adversely affect the rights of Seller or Buyer thereunder. Seller and Buyer will use their best efforts to obtain the consent of the other parties to any such Assigned Asset or
claim or right or any benefit arising thereunder for the assignment thereof to Buyer. Until the time any such consent is received, Seller shall be deemed to have assigned to Buyer hereby the economic benefit of Seller from and after the date hereof
under any such Assigned Asset and shall hold any such Assigned Asset in trust for Buyer, and Buyer shall have been deemed to have assumed the obligations of Seller from and after the Effective Date under any such Assigned Asset. If any such consent
is not obtained, or if an attempted assignment thereof would be ineffective or would adversely affect the rights of Seller thereunder so that Buyer would not in fact receive all such rights, the parties will cooperate in a mutually agreeable
arrangement under which Buyer would obtain the benefits and assume the obligations thereunder in accordance with this Agreement, including subcontracting, sub-licensing, or subleasing to Buyer, or under which
Seller would enforce for the benefit of Buyer, with Buyer assuming Seller’s obligations, any and all rights of Seller against a third party thereto. Seller will promptly pay to Buyer all monies received by Seller pursuant to any Assigned Asset
or any claim or right or any benefit arising thereunder from and after the Effective Date. 
 4.    Purchase
Price: The purchase price for the Assigned Assets shall be the fair market value agreed to be Five Hundred Thousand U.S. Dollars ($500,000.00 USD) plus applicable Swiss VAT of 8%. The Parties shall be entitled to amend this agreement in order to
determine another purchase price representing such fair market value, e.g. on advice by Cabrillo Advisors. For the avoidance of doubt, as of the Effective Date the Buyer hereby undertakes, assumes and promises to pay and to perform, satisfy and
discharge any future liabilities, duties, responsibilities and obligations of Seller arising out of the Assigned Assets. 

5.    Power of Attorney. Without limiting the above, Seller does hereby constitute and appoint Buyer, its
successors and assigns, as Seller’s true and lawful attorney-in-fact, with full power of substitution and resubstitution, for it and in its name, place and stead, but on behalf of and for the benefit of
Buyer, its successors and assigns: 
 a.    to demand and receive from time to time any and all Assigned
Assets conveyed, transferred and assigned to Buyer pursuant to this Agreement, and to give receipts and releases for and in respect of the same and any part thereof; 

b.    from time to time to institute and prosecute in its name or otherwise, but at the direction and
expense and for the benefit of Buyer and its successors and assigns, any and all proceedings at law, in equity or otherwise, which Buyer, its successors or assigns may deem proper in order to collect, assert or enforce any claim, right or title of
any kind in and to the Assigned Assets transferred and assigned to Buyer pursuant to this Agreement, and to defend and compromise any and all actions, suits and proceedings in respect of any of said property, assets and business and to do any and
all such acts and things in relation thereto as Buyer, its successors or assigns shall deem advisable; and 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 c.    to do all other things legally permissible or
reasonably deemed by Buyer to be required to recover the assets conveyed by Seller, hereby declaring that the appointment hereby made and the powers hereby granted are coupled with an interest and are and shall be irrevocable by Seller in any manner
or for any reason. 
 6.    Representations and Warranties. Each of Seller and Buyer, as applicable, represents
on behalf of itself to the other as follows: 
 a.    each party (i) is a limited liability company,
with restricted liability, duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, and (ii) is qualified to do business and is in good standing as a foreign corporation or
organization in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such qualification would prevent such party from performing its obligations under this
Agreement; 
 b.    each party has the requisite power and authority and has taken all action necessary
in order to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby; 

c.    this Agreement has been duly executed and delivered by it and constitutes a valid and binding
agreement of it enforceable in accordance with the terms hereof, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar laws relating to the enforcement of creditors’ rights generally and by
general principles of equity; 
 d.    the execution, delivery and performance of this Agreement by each
party does not: (i) violate any law, regulation, order, writ, decree, determination or award of any court, governmental or administrative or other agency having jurisdiction over such party, or (ii) conflict with, or constitute a default
under, any agreement, instrument or understanding, or court or administrative order, oral or written, to which such party is a party or by which such party is bound; and 

e.    The Seller represents and warrants to the Buyer that to the knowledge of the Seller the Seller is the
legal and beneficial owner of, and has good and marketable title to all of the Assigned Assets, free and clear of all liens, claims, charges and encumbrances. 

The representations and warranties set out in this Agreement, and all covenants of the parties set out in this Agreement will survive the Closing and,
notwithstanding such Closing, will continue in full force and effect for the benefit of the Buyer or the Seller, as the case may be, in accordance with the terms thereof. 

7.    Further Assurances. Seller will, from time to time, execute and deliver, or cause to be executed and
delivered, such additional instruments, notices, releases, certificates, 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
powers of attorney, assurances, bills of sale, and other documents and do all such further acts, assignments, transfers and other things, as may reasonably be requested by Buyer in order to more
completely assign and transfer the Assigned Assets, and for the effective confirmation, consummation and particularization of this Agreement, including but not limited to updating registrations in the respective jurisdictions. 

8.    Costs and Expenses. Each of the parties hereto shall pay its own expenses and costs incurred or to be
incurred in negotiating, closing and executing the transactions contemplated by this Agreement. The Buyer shall be responsible for any applicable taxes payable, if any, as a result of the transfer of the Assigned Assets except for Swiss VAT that is
payable by the Seller. 
 9.    Severability. If any provision of this Agreement of the application thereof to
any person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to persons or circumstances or in jurisdictions other than
those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby
is not affected in any manner adverse to any party. 
 10.    Entire Agreement. This Agreement constitutes the
final agreement between the parties with respect to the subject matter contained herein, and is the complete and exclusive statement of the parties’ agreement on the matters contained herein. All prior and contemporaneous negotiations and
agreements between the parties with respect to the matters contained herein are superseded by this Agreement. 

11.    Amendments and Waiver. No modification, waiver or amendment of this Agreement shall be binding unless
executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof unless otherwise expressly provided. 

12.    Binding Effect. This Agreement shall be binding upon and inure to the benefit of the respective successors
and assigns of the parties hereto. This Agreement does not confer rights on any person other than the parties to this agreement and their successors and Buyers. 

13.    Governing Law. This Agreement and all matters relating thereto and arising therefrom shall be governed by,
administered under and construed in accordance with the laws of Switzerland, without reference to provisions of conflicts of laws, and the courts of Basel/Switzerland shall have exclusive jurisdiction with respect thereto 

14.    Counterparts. This Agreement may be executed in two or more counterparts and by facsimile signature, each of
which shall be deemed an original, but all of such counterparts together shall constitute one and the same instrument. The signatures of both parties need not appear on the same document. The delivery of signed counterparts by facsimile or email
transmission that includes a copy of a sending party’s signature is as effective as signing and delivering the counterpart in person. 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 15.    Successors and Assigns. This Agreement shall be binding on and
inure to the benefit of the parties hereto, their successors in interest and assigns. 
 [signature page follows] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 IN WITNESS WHEREOF, this Agreement has been duly executed by the undersigned as of the date set
forth above. 
  

			
	The Seller: Urovant Sciences GmbH
		
	By:	 	/s/ Marianne Romeo Dinsmore
	Name:	 	Marianne Romeo Dinsmore
	Title:	 	Managing Director
	Date:	 	12 June 2017
	Place:	 	Bermuda

 WITNESS 1: 
  

			
		
	By:	 	/s/ Melissa Butler
	Name:	 	Melissa Butler

 WITNESS 2: 
  

			
		
	By:	 	/s/ Christie Meacham
	Name:	 	Christie Meacham

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 ATTESTATION 

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine
signature of Ms. Marianne Romeo Dinsmore, citizen of the United States of America, residing in Hamilton, Bermuda; acting for Urovant Sciences GmbH, in Basel, Switzerland, as Managing Director, with single signature.

 The authenticity of the signature was established by means of comparison. 

BASEL, Switzerland, this 26th (twenty-sixth) day of June 2017 (two thousand and seventeen) 

 

	
	
	/s/ Matthias Staehelin

 Leg.Prot.Nr. 1285/2017 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
			
	The Buyer: Roivant Sciences GmbH
		
	By:	 	/s/ Ruben Masar
	Name:	 	Ruben Masar
	Title:	 	Secretary
	Date:	 	12 June 2017
	Place:	 	Basel, Switzerland

 WITNESS 1: 
  

			
		
	By:	 	/s/ Silvia Plattner
	Name:	 	Silvia Plattner

 WITNESS 2: 
  

			
		
	By:	 	/s/ Sebastian Flickiger
	Name:	 	Sebastian Flickiger

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 ATTESTATION 

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine
signature of Mr. Ruben Masar, citizen of Basel, Switzerland, residing in Basel, Switzerland; acting for Roivant Sciences GmbH, in Basel, Switzerland, as authorized signatory, with single signature. 

The authenticity of the signature was established by means of comparison. 

BASEL, Switzerland, this 26th (twenty-sixth) day of June 2017 (two thousand and seventeen) 

 

	
	
	/s/ Matthias Staehelin

 Leg.Prot.Nr. 1285/2017 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 SCHEDULE I 

ASSIGNED ASSETS 

Agreements: 
  

	 	•	 	Assets as set forth in the License Agreement between MERCK SHARP & DOHME CORP. and UROVANT SCIENCES GMBH dated February 3, 2017 as amended on April 27, 2017 and as may be amended from time to time
solely as it relates to any rights or obligations in China 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 AMENDMENT NO. 1 TO CHINA IP PURCHASE AGREEMENT 

THIS AMENDMENT NO. 1 TO CHINA IP
PURCHASE AGREEMENT (this “Amendment”) is entered into as of May 22, 2018 (“Amendment Effective Date”), by and between Urovant Sciences GmbH, a Switzerland limited liability
company with an address of 8 Viaduktstrasse, 4051 Basel, Switzerland (“Seller”) and Roivant Sciences GmbH, a Switzerland limited liability company with an address of 8 Viaduktstrasse, 4051 Basel, Switzerland
(“Buyer”). Each of the Seller and the Buyer are referred to in this Agreement as a “party” and together as the “parties.” 

RECITALS 

WHEREAS, Seller and Buyer entered into that certain China IP Purchase Agreement (the “Purchase
Agreement”), dated as of June 12, 2017 (the “Original Agreement Date”); 

WHEREAS, prior to the Original Agreement Date Seller in-licensed
certain intellectual property rights with respect to the Product (defined below) from Merck (as defined below) pursuant to the Merck Agreement (as defined below) in all countries of the world outside of the Kyorin Territory (defined below) with
respect to Licensed Compounds and Products (both as defined below); 
 WHEREAS, Seller has certain
obligations to Merck with respect to such intellectual property rights arising from the conduct of development or commercialization of Licensed Compounds and Products throughout the licensed territory, including in China; and 

WHEREAS, Seller and Buyer desire to amend the Purchase Agreement as set forth herein; and 

NOW THEREFORE, in consideration of the mutual agreements, covenants and considerations
contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows, in accordance with Section 11 of the Purchase Agreement: 

ARTICLE 1 

DEFINITIONS 

As used in this Amendment, all capitalized terms, whether used in the singular or plural form, will have the meanings set forth below or in
the Agreement. 
 “Kyorin Territory” means Japan, Brunei, Cambodia, Hong Kong, Indonesia, Korea, Laos, Malaysia, Myanmar,
Philippines, Singapore, Taiwan, Thailand and Vietnam. 
 “Licensed Compound” shall have the meaning assigned to it under
the Merck Agreement, and includes Vibegron. 
 “Merck” means Merck Sharpe & Dohme, Corp., a corporation organized
and existing under the laws of the State of New Jersey, Unites States of America. 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 “Merck Agreement” means the License Agreement by and between Merck and Seller,
dated February 3, 2017, as amended on April 27, 2017 and as may be further amended from time to time. 

“Product” means any and all pharmaceutical products with any kinds of strength, dosage form, and formulations containing
Vibegron or any other Licensed Compound as an active pharmaceutical ingredient, either alone or in combination with one or more other active pharmaceutical ingredient(s). 

“Transferee” means any of Buyer’s assignees, licensees, sublicensees or any other party that receives or benefits from
Buyer’s rights under this Agreement, whether directly or indirectly, to develop and commercialize any Product in China. 

“Third Party” a person or entity other than Seller or Buyer, or any of their affiliates. 

“Vibegron” means the chemical compound identified as [***] 

ARTICLE 2 

AMENDMENTS 

2.1    Section 1 of the Purchase Agreement is hereby amended and restated in its entirety to read as follows: 

“1.    Sale of Assigned Assets. Seller hereby sells, transfers, assigns, conveys, grants and delivers to Buyer,
“as-is,” “where-is” and with all faults, effective as of the Effective Date, to have and to hold forever, all of Seller’s right, title, claim
and interest in and to (i) any and all intellectual property rights which constitute improvements to the intellectual property licensed to Seller, or arise from the activities conducted by Seller with respect to Licensed Compounds and Products,
under the Merck Agreement, whether existing as of the Original Agreement Date or hereafter, solely in China, including but not limited to, inventions (whether patentable or not), patents, patent applications, trademarks, trade names, service names,
domain names, trade dress, copyrights, works of authorship, trade secrets, know-how, data, intellectual property license agreements and any other proprietary information (including all rights to sue and
recover and retain damages, costs and attorneys’ fees for past, present and future infringement and any other rights relating to any of the foregoing), and further including any moral rights and/or goodwill and activities associated with any of
the foregoing, in all cases solely in China; or (ii) the Merck Agreement solely as it relates to any rights and obligations in or for China; (collectively, items in clauses (i) and (ii), the “Assigned Assets”).” For
clarity, no assignment is made hereunder by Seller with respect to any intellectual property rights arising under any license agreement other than the Merck Agreement, or acquired or otherwise obtained by Seller and which relate to compounds or
products which are other than the Licensed Compounds or Products. 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 2.2    Section 3 of the Purchase Agreement is hereby amended and
restated in its entirety to read as follows: 
 “3.    Compliance with Merck Agreement; Assignment of Agreements
and Rights.  
 (a)    Buyer hereby acknowledges that the Assigned Assets comprise in part
intellectual property owned by Merck, and that Buyer’s use and enjoyment of such Assigned Assets remain subject at all times to the terms of the Merck Agreement. Buyer acknowledges that it has been provided a complete copy of the Merck
Agreement prior to the Amendment Effective Date. 
 (b)    Anything in this Agreement to the contrary
notwithstanding, this Agreement shall not constitute an agreement to assign, or an assignment of, any Assigned Asset or any claim or right or any benefit arising thereunder or resulting therefrom if an attempted assignment thereof would constitute a
breach or other contravention thereof or in any way adversely affect the rights of Seller or Buyer thereunder. Seller and Buyer will use their best efforts to obtain the consent of the other parties to any such Assigned Asset or claim or right or
any benefit arising thereunder for the assignment thereof to Buyer. Until the time any such consent is received, Seller shall be deemed to have assigned to Buyer hereby the economic benefit of Seller from and after the date hereof under any such
Assigned Asset and shall hold any such Assigned Asset in trust for Buyer, and Buyer shall have been deemed to have assumed the obligations of Seller from and after the Effective Date under any such Assigned Asset. If any such consent is not
obtained, or if an attempted assignment thereof would be ineffective or would adversely affect the rights of Seller thereunder so that Buyer would not in fact receive all such rights, the parties will cooperate in a mutually agreeable arrangement
under which Buyer would obtain the benefits and assume the obligations thereunder in accordance with this Agreement, including subcontracting, sub-licensing, or subleasing to Buyer, or under which Seller would
enforce for the benefit of Buyer, with Buyer assuming Seller’s obligations, any and all rights of Seller against a Third Party thereto. Seller will promptly pay to Buyer all monies received by Seller pursuant to any Assigned Asset or any claim
or right or any benefit arising thereunder from and after the Effective Date. 
 2.3    Section 4 of the Purchase
Agreement is hereby amended and restated in its entirety to read as follows: 
 “4.    Consideration 

(a)    Purchase Price. The purchase price for the Assigned Assets shall be the fair market value of
the Assigned Assets, agreed to be One Million Eight Hundred and Ten Thousand U.S. Dollars ($1,810,000.00 USD) plus applicable Swiss VAT of 8% (the “Purchase Price”). Within thirty (30) days following the execution of this
Amendment, the Buyer shall pay the Seller the Purchase Price minus any amount that the Buyer has already paid to the Seller under Section 4 of the Purchase Agreement prior to the execution of this Amendment. For the avoidance of doubt, as of
the Original Agreement Date, the Buyer 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
hereby undertakes, assumes and promises to pay and to perform, satisfy and discharge any future liabilities, duties, responsibilities and obligations of Seller arising out of the Assigned Assets.

 (b)    Royalty and Milestone Payments. Buyer shall pay to Seller or Seller’s designee:

 (i)    any royalties owed under the Merck Agreement with respect to Net Sales (as defined in the Merck
Agreement) of the Product at the maximum royalty rate (i.e., assuming sales at the upper tier of the royalty rates) pursuant to the Merck Agreement terms, to the extent that such payment obligation arises out of the sale or use of the Product by
Buyer or its Transferees (if any) in China pursuant to this Agreement (including, where applicable, any damages, settlement fees or other amounts recovered by Buyer with respect to the Product in China); 

(ii)    any development or regulatory milestone payment pursuant to the Merck Agreement, to the extent that
such payment obligation arises out of the development or regulatory approval or use of Products by Buyer or its Transferees (if any) in or for China pursuant to this Agreement; including without limitation and for the avoidance of doubt, Buyer shall
pay to Seller [***]; and 
 (iii)    a pro rata percentage of any other payment, including any commercial
milestone payment, under the Merck Agreement, such percentage being commensurate with the sales achieved in China by Buyer or its Transferees (if any) as a percentage of the global sales that trigger such other payment under the Merck Agreement.

 (c)    Payment Terms. All payments due to Seller or its designee under Section 4(b) of
this Agreement shall be paid by Buyer in United States dollars by wire transfer within thirty (30) days after a milestone or event that triggers a royalty payment is achieved. Net sales recorded in any foreign currency shall be converted into
United States dollars in a manner consistent with Seller’s customary and usual conversion procedures used to prepare its audited financial statements for external reporting purposes, provided that such practices use a widely accepted source of
published exchange rates. Each party shall be responsible for paying its own banking fees associated with the transfer of funds. 

ARTICLE 3 

MISCELLANEOUS 

3.1    Effect of Amendment. Except as specifically amended hereby, the Purchase Agreement shall continue in
full force and effect. In the event of any inconsistency or conflict between the Purchase Agreement and this Amendment, the terms, conditions and provisions of 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
this Amendment shall govern and control. This Amendment and the Purchase Agreement constitute the full and entire understanding and agreement between the parties regarding the matters set forth
herein. 
 3.2    Severability. If any provision of this Amendment or the application thereof to any
person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to persons or circumstances or in jurisdictions other than those as
to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not
affected in any manner adverse to any party. 
 3.3    Amendments and Waivers. No modification, waiver or
amendment of this Amendment shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Amendment shall be deemed or shall constitute a waiver of any other provision hereof unless otherwise expressly
provided. 
 3.4    Successors and Assigns. This Amendment shall be binding on and inure to the benefit of
the parties hereto, their successors in interest and assigns. 
 3.5    Governing Law. This Amendment all
matters relating thereto and arising therefrom shall be governed by, administered under and construed in accordance with the laws of Switzerland, without reference to provisions of conflicts of laws, and the courts of Basel/Switzerland shall have
exclusive jurisdiction with respect thereto. 
 3.6    Counterparts. This Amendment may be executed in two
or more counterparts and by facsimile signature, each of which shall be deemed an original, but all of such counterparts together shall constitute one and the same instrument. The signatures of both parties need not appear on the same document. The
delivery of signed counterparts by facsimile or email transmission that includes a copy of a sending party’s signature is as effective as signing and delivering the counterpart in person. 

[Signature pages follow] 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 IN WITNESS WHEREOF, the foregoing AMENDMENT
NO. 1 TO CHINA IP PURCHASE AGREEMENT is hereby executed as of the date first above written. 

 

					
	SELLER:
	
	UROVANT SCIENCES GMBH
		
	By:	 	/s/ Sascha Bucher
		 	Name:	 	Sacha Bucher
		 	Title:	 	Head of Global Transactions
	
	WITNESS 1:
		
	By:	 	/s/ Bobby Thakrar
		 	Name:	 	Bobby Thakrar
		 	Title:	 	Manager, Accounting Services
	
	WITNESS 2:
		
	By:	 	/s/ Dominik Hemmig
		 	Name:	 	Dominik Hemmig
		 	Title:	 	Principal and Head of Legal, RoivantNext

  
 [Signature page to
Amendment No. 1 to China IP Purchase Agreement] 
  

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

					
	BUYER:
	
	ROIVANT SCIENCES GMBH
		
	By:	 	/s/ Sascha Bucher
		 	Name:	 	Sacha Bucher
		 	Title:	 	Head of Global Transactions
	
	WITNESS 1:
		
	By:	 	/s/ Bobby Thakrar
		 	Name:	 	Bobby Thakrar
		 	Title:	 	Manager, Accounting Services
	
	WITNESS 2:
		
	By:	 	/s/ Dominik Hemmig
		 	Name:	 	Dominik Hemmig
		 	Title:	 	Principal and Head of Legal, RoivantNext

  
 [Signature page to
Amendment No. 1 to China IP Purchase Agreement] 
  

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]